JOHNSON & JOHNSON is 2.0x more valuable than Merck & Co., Inc. by market capitalization ($573.98 B vs $293.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MRK | JNJ |
|---|---|---|
| Market cap | $293.16 B | $573.98 B |
| US-listed rank | #44 | #20 |
| Revenue (latest FY) | $65.01B | $94.19B |
| Net income (latest FY) | $18.25B | $26.80B |
| Net margin | 28.1% | 28.5% |
| P/E (trailing FY) | 16.1 | 21.4 |
| SEC filings | 996 | 984 |
JOHNSON & JOHNSON is 2.0x more valuable than Merck & Co., Inc. by market capitalization ($573.98 B vs $293.16 B).
In their latest fiscal years, Merck & Co., Inc. reported $65.01B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Merck & Co., Inc. and JOHNSON & JOHNSON, or browse the full rankings.